Moderna, Inc. Furnishes and FY 2025 Financial Results and Business Updates
Summary
Moderna, Inc. (NASDAQ:MRNA) furnished its financial results for the fourth quarter and full year ended December 31, 2025, via an Exhibit 99.1 press release on February 13, 2026. For , the company reported revenue of $0.7 billion, a GAAP net loss of $(0.8) billion, and GAAP EPS of $(2.11). Full-year 2025 results included revenue of $1.9 billion, a GAAP net loss of $(2.8) billion, and GAAP diluted EPS of $(7.26). * The company reiterates its plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. * Its influenza vaccine filing was accepted for regulatory review in the EU, Canada, and Australia, but received a Refusal-to-File letter from the U.S. FDA. * The Norovirus Phase 3 trial is fully enrolled, with data expected in 2026. * The Phase 2 intismeran autogene trial in muscle invasive bladder cancer is also fully enrolled.
Why It Matters
Investors should note the significant GAAP net losses for both Q4 and full-year 2025, alongside the reiterated plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. The U.S. FDA's Refusal-to-File letter for the influenza vaccine filing, despite acceptances elsewhere, represents a material regulatory setback for a key pipeline asset.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Friday, February 13, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral